Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(64)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NYfrO21kS3m2b4TvfIlkKEG|c3H5 MWGxNEBvVQ>? NHKxNWc4OiCq MVvEUXNQ NGCyRYRRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MoTuNlQ6ODB6N{O=
HT-29 MUPDfZRwfG:6aXOgRZN{[Xl? M4\CT|ExKG6P MlntO|IhcA>? NVuwcG5[TE2VTx?= Mnu3VI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NXvhR5JWOjR7MEC4O|M>
HT-29 M4XlSGN6fG:2b4jpZ{BCe3OjeR?= MWSxNEBvVQ>? MoT1O|IhcA>? MnfJSG1UVw>? MYnQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> M2Dxb|I1QTByOEez
PC3 NUTw[2lNU2mwYYPlJGF{e2G7 MlLUNVAxKG6P MVexJIg> M3XnOWROW09? NX\kbnZpWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> Mm[1NlE6Pzh4OEO=
PC3 MWfLbY5ie2ViQYPzZZk> M1S1S|ExOCCwTR?= MUSxJIg> MYDEUXNQ NI\OVFhFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NH\2dpMzOTl5OE[4Ny=>
PC3 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlntNU42KM7:TR?= MmjINUBp MVTEUXNQ MXzJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? NFroOHczOTl5OE[4Ny=>
HEK293 MVnGeY5kfGmxbjDBd5NigQ>? NW[yPIY{OTByIH7N MX24JIg> NH7YSWNFVVOR NIP3c2ZKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NHvTcXczOTV|OUOwNS=>
BT-20 NGPYWYtMcW6jc3WgRZN{[Xl? NE\BcngzOCEQvF2= NG\Fd4JFVVOR NUOyb5VqTG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= M3HT[VIyOzV|NUWx
U937 NHXXPW5CdnSrYnHjeIVzcWGuIFHzd4F6 NWPYOnluPTBizszN NYH3enNWPDhiaB?= MkX1SG1UVw>? M3jEO2lv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NHXIXJczOTF2MkGwOi=>
U937 MknHRY51cWKjY4TldolidCCDc4PhfS=> NUXSbItuPTBizszN MX60PEBp NIHNU|hFVVOR NXfm[VY6TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NXrzdZlmOjFzNEKxNFY>
U937 MnHIRY51cWKjY4TldolidCCDc4PhfS=> MYS1NEDPxE1? NGf2NpY1QCCq NWeyNIdbTE2VTx?= M{fYSmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ MkD2NlEyPDJzME[=
MCF-7 NVjBcGszSXW2b4DoZYd6KEG|c3H5 M3HiNVMxKG6P MkL3OEBp MW\EUXNQ MXvJcoR2[2W|IHH1eI9xcGGpeR?= M1LQbVIxODJ6MUO0
U87MG M17zXGtqdmG|ZTDBd5NigQ>? MljYNUDPxE1? MYK2JIg> MXnEUXNQ M4LhT3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MnH3NVk5PDh2MES=
U87MG M125OmtqdmG|ZTDBd5NigQ>? NIfSemIyKM7:TR?= M2X5NlYhcA>? MWHEUXNQ Ml7XVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M{jzO|E6QDR6NEC0
U87MG MV\LbY5ie2ViQYPzZZk> Mnf2NUDPxE1? MmHhOkBp NFXwUIxFVVOR M3q0Z2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MWSxPVg1QDRyNB?=
U87MG M4DlZmtqdmG|ZTDBd5NigQ>? NV3zT5Z{OSEQvF2= Ml3iOkBp M4OwWGROW09? M{Hib2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? MnPsNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb M4jkN2F2fG:yaHHnfUBCe3OjeR?= MWOwMlIh|ryP NHLFVoMzPCCq M4rvb2ROW09? M2Hrbmlv\HWlZYOgZZV1d3CqYXf5 MVyxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 M4i1V2F2fG:yaHHnfUBCe3OjeR?= MmrvNE4zKM7:TR?= MVKyOEBp NIrQfYlFVVOR M{G2ZWlv\HWlZYOgZZV1d3CqYXf5 NXXHR4VtOTh|OUG5OFk>
H4 NGXOT4hHfW6ldHnvckBCe3OjeR?= NGnFeG4xNjJizszN NF\oXpEzPCCq NGDUVm1FVVOR MYDJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NFvsNmwyQDB{NEW4OC=>
HeLa NWezNYRZTnWwY4Tpc44hSXO|YYm= M4DaV|ExOCCwTR?= NX7QdpBROzZiaB?= MnXFSG1UVw>? MX3JcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u M13rOlE4PTZ|M{i1
HeLa NHzLW5JHfW6ldHnvckBCe3OjeR?= MlPzNVAxKG6P MmnFN|YhcA>? NHvJcFRFVVOR MmjVTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NWf4UYt5OTd3NkOzPFU>
HeLa MV3GeY5kfGmxbjDBd5NigQ>? NWS4dlh1OTByIH7N MlPrN|YhcA>? NH\UdG1FVVOR Mn3WTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u M3TxclE4PTZ|M{i1
SYF MoK3SpVv[3Srb36gRZN{[Xl? MnjJNVAxKG6P Mk\zNlQhcA>? MmLaSG1UVw>? NW\V[HhGUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MVmxO|U3OzN6NR?=
SYF MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;mV|ExOCCwTR?= NH\ubo4zPCCq NUXE[FkxTE2VTx?= NFLyV45KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NUjBcmRROTd3NkOzPFU>
HEK293T M{n2UGFvfGm4aYLhcEBCe3OjeR?= MX2xJI5O MoL2OEBl M1XGTWROW09? MUTJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= NULyOIpQOTd2OEW1NFE>
HEK293T NGLrdXpCdnSrdnnyZYwhSXO|YYm= M1ixSFEhdk1? NUTzXXRiPCCm MmLiSG1UVw>? NGDURYNKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MoTwNVc1QDV3MEG=
PBMC NGnPV2FHfW6ldHnvckBCe3OjeR?= M1njXFEhdk1? NY\LdotDOTRiZB?= NFnaN|hFVVOR MYXS[YR2[2W|IFPDVlUh\GWwc3n0fS=> Mly5NVc1QDV3MEG=
PBMC MX\GeY5kfGmxbjDBd5NigQ>? MonoNUBvVQ>? NGTGeoEyPCCm NXiyS3pLTE2VTx?= NHK5RlZFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? MnS2NVc1QDV3MEG=
HEK293 cells MmW3T4lv[XOnIFHzd4F6 MVK1NEBvVQ>? M2iz[VQ2KG2rbh?= NYmxWI5bTE2VTx?= NH;ibIpKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P Mk[5NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MoPoSpVv[3Srb36gRZN{[Xl? NX3ic|JGOTByIH7N M{PaTlQhcA>? NFfBVJNFVVOR MWPJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> NULVZ2NHOTdzMkiyOlI>
Human mixed lymphocyte MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yS2c2KG6P M3nKVmROW09? MnzSTWM2OD1zLk[gcm0v MXyxOlE5PTh4NR?=
Lewis rat lymph node cells NVfsTlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXRbWFuPSEQvF2= MYrEUXNQ NXjuSWVvUUN3ME2yMlYh|ryP NE\GXY4yPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDKdJBPOTBibl2= M3LlRlczKGh? NIPPbJdFVVOR NGLXXJVKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NYraTFVzOTByMkG5OFg>
MRK-nu-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrpeZZKSzVyPUCuPFQ2KHCP MoXrV2FPT0WU
OCUB-M Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwMkSgdG0> M3;x[XNCVkeHUh?=
SF539 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFzLk[gdG0> MYDTRW5ITVJ?
ES4 NH:4NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLVTWM2OD1{MT61JJBO NVO3VndlW0GQR1XS
RL95-2 NX;mZoxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xNJpKSzVyPUGwO{BxVQ>? MVLTRW5ITVJ?
LC-2-ad MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPiVYFoUUN3ME20NlMheE1? NWTNUFJEW0GQR1XS
Daudi MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr4cmpKSzVyPUSzOEBxVQ>? MWTTRW5ITVJ?
NTERA-S-cl-D1 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LQbGlEPTB;NESzJJBO NHXmU|NUSU6JRWK=
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\3WmlEPTB;NkWyJJBO MVfTRW5ITVJ?
VA-ES-BJ NWnmbFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP2TWM2OD15MkOgdG0> MkK4V2FPT0WU
GR-ST M1;uSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4OWlEPTB;OES2JJBO M1\kfXNCVkeHUh?=
SW872 M4HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKxRmhxUUN3ME24OFYheE1? M2fyRnNCVkeHUh?=
NOS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r3b2lEPTB;OEexJJBO NXzxdFhXW0GQR1XS
MC116 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD17OEWgdG0> M1LKUnNCVkeHUh?=
NCI-H1355 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqx[ndKSzVyPUGuNFEhdk1? M4DIN3NCVkeHUh?=
RPMI-8226 NF23NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHjSG5zUUN3ME2xMlE6KG6P MkHWV2FPT0WU
TE-15 NFvXOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwM{[gcm0> MlHCV2FPT0WU
Ramos-2G6-4C10 M1raRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwNE[gcm0> M2rLdXNCVkeHUh?=
KU812 NETrTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nHO2lEPTB;Mj6wNUBvVQ>? MknEV2FPT0WU
EW-1 M3y2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\meWlEPTB;Mj6xO{BvVQ>? NH7zNVRUSU6JRWK=
KS-1 NIG4e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjHTFdKSzVyPUKuOFUhdk1? MonNV2FPT0WU
SK-LMS-1 M2XuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qwdWlEPTB;Mj60PUBvVQ>? MWXTRW5ITVJ?
TGBC1TKB NGm1XnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljDTWM2OD1{Lk[5JI5O MXrTRW5ITVJ?
TE-6 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpTWM2OD1{Lke3JI5O NVPRRmJSW0GQR1XS
ETK-1 M130XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwOEKgcm0> MVzTRW5ITVJ?
BE-13 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwOUmgcm0> NFTnZmxUSU6JRWK=
A3-KAW NYW5d2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPoW3F[UUN3ME2yMlk6KG6P NH7mO3BUSU6JRWK=
TE-10 NE\zdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnFNVNrUUN3ME2zMlMhdk1? MUjTRW5ITVJ?
DOHH-2 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nuNmlEPTB;Mz6zOUBvVQ>? MXnTRW5ITVJ?
ES6 M1LPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwNEOgcm0> M4rYfXNCVkeHUh?=
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;PTWM2OD12LkG1JI5O MVfTRW5ITVJ?
SH-4 M2fveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTKTWM2OD12LkO0JI5O MWrTRW5ITVJ?
NB13 NEDjUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwM{[gcm0> M3ewcHNCVkeHUh?=
HUTU-80 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTRwNEKgcm0> MYfTRW5ITVJ?
CCRF-CEM M4fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYixPFcxUUN3ME20Mlk1KG6P MWnTRW5ITVJ?
TGBC24TKB NEi4UpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK5e3JZUUN3ME21MlUyKG6P M1T1XHNCVkeHUh?=
697 NIXhXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rvT2lEPTB;Nj6yPEBvVQ>? M1TZV3NCVkeHUh?=
J-RT3-T3-5 NFfwTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBW21KSzVyPU[uOFYhdk1? NEDSd2tUSU6JRWK=
KALS-1 NFvW[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwNU[gcm0> NHzaSldUSU6JRWK=
no-10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD15LkK5JI5O NFr0fIlUSU6JRWK=
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThwN{mgcm0> MXjTRW5ITVJ?
L-540 M3zCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Gx[mlEPTB;MUCuOFIhdk1? M4HGWHNCVkeHUh?=
JiyoyeP-2003 NVzxTmV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFyLkm0JI5O NIe1TItUSU6JRWK=
HH MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLkO5JI5O MoX4V2FPT0WU
SR M17H[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFzLkS1JI5O MnvvV2FPT0WU
QIMR-WIL NX\nVXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr5ZZpKSzVyPUGxMlg2KG6P MlvSV2FPT0WU
A4-Fuk M1LEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;tUWlEPTB;MUOuNVIhdk1? Ml24V2FPT0WU
CESS NF\heXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF|LkGzJI5O M3W2OXNCVkeHUh?=
KE-37 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD1zNj6wO{BvVQ>? MmPEV2FPT0WU
SK-UT-1 M{DYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf6VWdKSzVyPUG2MlgyKG6P MojaV2FPT0WU
SIG-M5 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF5LkK1JI5O NXT1PIVlW0GQR1XS
HT NEXuV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\v[ppKSzVyPUG3MlYhdk1? Mo\pV2FPT0WU
DEL M1iwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzCTWM2OD1zNz65PUBvVQ>? MVzTRW5ITVJ?
SK-PN-DW M1u4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\BfHBKSzVyPUKwMlI{KG6P NH;MOYpUSU6JRWK=
RPMI-8402 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mzN2lEPTB;MkGuO|chdk1? NGHiS|BUSU6JRWK=
RPMI-6666 M4H4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXJTWM2OD1{ND60NkBvVQ>? MmrTV2FPT0WU
NCI-H720 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULsdYNPUUN3ME2yOU41OSCwTR?= NVu0c4huW0GQR1XS
EW-16 NF:zbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrTR3pKSzVyPUK2Mlg4KG6P NXXzfYpWW0GQR1XS
BL-70 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ6LkO4JI5O NWPhSJVPW0GQR1XS
SF126 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNcmRiUUN3ME2zNE4{QCCwTR?= NFLZZYJUSU6JRWK=
BC-1 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G3R2lEPTB;M{GuNlYhdk1? NHjLZZpUSU6JRWK=
MHH-PREB-1 NF3IeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD1|Mj60OEBvVQ>? NV:0U3ZzW0GQR1XS
A101D M3fRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO1OIFlUUN3ME2zNk43OiCwTR?= NY[zbXREW0GQR1XS
NMC-G1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLFUoQ6UUN3ME2zN{43PyCwTR?= MULTRW5ITVJ?
LB1047-RCC M1vtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTsTWM2OD1|ND62PUBvVQ>? Ml;sV2FPT0WU
EM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf1fWx1UUN3ME2zPE42OyCwTR?= NHHz[IRUSU6JRWK=
COLO-684 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\n[GlEPTB;M{muPEBvVQ>? MV\TRW5ITVJ?
Becker M{\UTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSxXnVIUUN3ME20NU4xPSCwTR?= MlH0V2FPT0WU
BL-41 M{fmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT2V5FKSzVyPUSzMlY3KG6P NEmxR|lUSU6JRWK=
MDA-MB-134-VI MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m5UmlEPTB;NESuNFIhdk1? MoHvV2FPT0WU
L-363 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTwTWM2OD12ND63N{BvVQ>? MUHTRW5ITVJ?
ECC4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnsUIJKSzVyPUS0Mlc5KG6P NF\hdHFUSU6JRWK=
A388 NG\UUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GR|VKSzVyPUS0MlgzKG6P Mk\YV2FPT0WU
HEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn70TWM2OD12OT63PUBvVQ>? Mom0V2FPT0WU
RKO Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\hdJdKSzVyPUWwMlI6KG6P MWHTRW5ITVJ?
KINGS-1 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rpZWlEPTB;NUGuOVUhdk1? M4TJeHNCVkeHUh?=
EB-3 NH;2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrOPYZKSzVyPUWyMlY4KG6P M1zZVnNCVkeHUh?=
ARH-77 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH21XWZKSzVyPUWyMlghdk1? MoP2V2FPT0WU
GCIY M{\KZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe5SJpOUUN3ME21N{41PiCwTR?= NIH1UFBUSU6JRWK=
NCI-H1304 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTV5LkKyJI5O MnjsV2FPT0WU
KARPAS-299 M3jGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZzLkiyJI5O MYnTRW5ITVJ?
IA-LM NGHwN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37SO2lEPTB;NkiuNVMhdk1? MWLTRW5ITVJ?
GI-1 NILEPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTdyLkO5JI5O NEiycVdUSU6JRWK=
TE-11 M4Trdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTd5LkG3JI5O NFOw[2lUSU6JRWK=
LS-411N NYDifYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTd5LkW3JI5O NHXyflZUSU6JRWK=
no-11 NF\mTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4bFVKSzVyPUizMlI1KG6P M1nFe3NCVkeHUh?=
MV-4-11 M{jVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D2b2lEPTB;OEOuO|Mhdk1? MkDxV2FPT0WU
BV-173 NEfCS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD16Mz65O{BvVQ>? MXjTRW5ITVJ?
CMK MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHJXW1HUUN3ME24OE4yPiCwTR?= M3;kSnNCVkeHUh?=
LC4-1 M{nPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnNcow4UUN3ME24Ok44OiCwTR?= M2G0UHNCVkeHUh?=
COR-L279 NXjMZ21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\nTWM2OD16Nz6yOUBvVQ>? M1ToeXNCVkeHUh?=
NCI-H209 M1LuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTh5LkSxJI5O NUDFT4VZW0GQR1XS
Raji NFP0ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rHNWlEPTB;OEmuO|Ihdk1? NX7VSVF1W0GQR1XS
LB996-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzu[4FKSzVyPUmzMlQ{KG6P MWPTRW5ITVJ?
NCI-H526 M1ruemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl|LkW5JI5O NHW4WmtUSU6JRWK=
KGN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfYVI1KSzVyPUm2MlI6KG6P MonZV2FPT0WU
MOLT-4 M{jTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyTWM2OD17Nj63PUBvVQ>? NGLlWmxUSU6JRWK=
PF-382 M4DSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTqTWM2OD17Nj63PUBvVQ>? NWXoT|BUW0GQR1XS
BC-3 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7oTWM2OD17OT6xPEBvVQ>? MUTTRW5ITVJ?
KARPAS-422 NF;uVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPtUG5TUUN3ME2xNFIvODlibl2= NUe1b5VLW0GQR1XS
SBC-1 M3vDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFyNz63OUBvVQ>? NWLWeJdEW0GQR1XS
LC-1F Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD1zMEiuNFUhdk1? NFX4V5JUSU6JRWK=
GB-1 NXH5TIlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFyOT6wNkBvVQ>? NX7Jc2s1W0GQR1XS
SNB75 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HERmlEPTB;MUG5MlY6KG6P MnmyV2FPT0WU
BB65-RCC M2HKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fPVmlEPTB;MUG5Mlk{KG6P MnHIV2FPT0WU
NCI-N87 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lRWZ1UUN3ME2xNlEvQThibl2= MYfTRW5ITVJ?
IST-MEL1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzFfVV4UUN3ME2xNlIvOzhibl2= MnXsV2FPT0WU
HOP-62 NFzXeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[2c2I3UUN3ME2xNlYvQDlibl2= NXXLeY5zW0GQR1XS
ACN NE\leYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL6TWM2OD1zNE[uO|Uhdk1? NHjmR49USU6JRWK=
DMS-114 NVrzcmxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ZV2lEPTB;MUWwMlY4KG6P M3yx[3NCVkeHUh?=
MLMA M1\Zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjOZmpKSzVyPUG1PU45QCCwTR?= NWrHOXpIW0GQR1XS
HT-144 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX3TWM2OD1zNkWuOFMhdk1? NH3nO2dUSU6JRWK=
C2BBe1 NGPUPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD1zNkeuO|Yhdk1? MWTTRW5ITVJ?
L-428 NV[1XYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF5Nz63JI5O NYPyVoxPW0GQR1XS
DU-4475 NXnNTnR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:5TWM2OD1zOEeuOlghdk1? NHzQXJlUSU6JRWK=
CP67-MEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF7OT6zPEBvVQ>? NW\YfVc{W0GQR1XS
MEG-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJyMT65OkBvVQ>? Mke0V2FPT0WU
IST-SL2 NF[1[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC2[5Y2UUN3ME2yNFgvPjNibl2= MWDTRW5ITVJ?
ES8 NWr0fHBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ{NT65OEBvVQ>? NUX1[XdTW0GQR1XS
COLO-800 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ|NT6yPEBvVQ>? MlLzV2FPT0WU
MFH-ino MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ|NT64OEBvVQ>? M2nVbnNCVkeHUh?=
OVCAR-4 MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDVlBKSzVyPUKzO{4zPCCwTR?= MU\TRW5ITVJ?
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj3cnBKSzVyPUK0Nk44OSCwTR?= NFXDTHNUSU6JRWK=
EW-12 NGfIVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fPcGlEPTB;MkSzMlEhdk1? M1O1fHNCVkeHUh?=
HCC1599 M1\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrHbWJwUUN3ME2yOlEvPDdibl2= NELRd|NUSU6JRWK=
SJSA-1 NH\MfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ5MT60OkBvVQ>? M1zMR3NCVkeHUh?=
ST486 M2HwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LvVWlEPTB;Mkm2MlE1KG6P NEe3Um1USU6JRWK=
NOMO-1 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXtcIdKSzVyPUOwNE4zOSCwTR?= MUnTRW5ITVJ?
MN-60 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofJTWM2OD1|MEWuN|Ihdk1? NXWwb21iW0GQR1XS
HCC1187 M4Dkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rqXWlEPTB;M{C3MlI2KG6P NWDaOXhxW0GQR1XS
SW982 NEDWTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTpdY8{UUN3ME2zNVQvPzVibl2= MVzTRW5ITVJ?
LB647-SCLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\xOGlEPTB;M{K4MlcyKG6P MlHhV2FPT0WU
HC-1 NWHiN3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TkSGlEPTB;M{O1MlUhdk1? NXLBV3VCW0GQR1XS
EHEB M1L4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LIbGlEPTB;M{O3MlUzKG6P NV\YU4NoW0GQR1XS
TUR NFLqc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1|NkOuPVUhdk1? NHnhUXdUSU6JRWK=
LU-139 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN5OD6wNkBvVQ>? MX3TRW5ITVJ?
NB1 NFLEcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnPendWUUN3ME2zPFQvPDVibl2= M1rJZXNCVkeHUh?=
BB30-HNC M4jLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH5VJhCUUN3ME2zPFgvOzJibl2= M4\zcHNCVkeHUh?=
HAL-01 M1ywN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;qTWM2OD1|OEmuNlYhdk1? M{fMVXNCVkeHUh?=
K5 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP3TWM2OD12MUGuN|chdk1? NIHNRXhUSU6JRWK=
MZ2-MEL NUPDdnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTRzMz62OEBvVQ>? NVLpSIlUW0GQR1XS
RXF393 NXrWVnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n2RmlEPTB;NEG2MlQ2KG6P Mon1V2FPT0WU
NCI-H1648 M1f1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRzNz61N{BvVQ>? Ml7OV2FPT0WU
TE-12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR|ND6yOkBvVQ>? NF3KbYVUSU6JRWK=
EoL-1- MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTR|Nz65PEBvVQ>? MVPTRW5ITVJ?
JAR NIXvRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD12M{iuOlIhdk1? Mn61V2FPT0WU
DSH1 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzDTZpzUUN3ME20OVgvQTFibl2= M1PKT3NCVkeHUh?=
NCI-H187 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR4Mj64NUBvVQ>? NGXHe3lUSU6JRWK=
HCE-4 NX33cWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLCcXRKSzVyPUS3O{43PiCwTR?= Mk\nV2FPT0WU
8-MG-BA NEfSWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TTVGlEPTB;NUixMlUzKG6P MofPV2FPT0WU
KLE MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTV6NT6yJI5O Ml[3V2FPT0WU
KNS-42 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPXTWM2OD13OE[uPFEhdk1? M4XCPXNCVkeHUh?=
MSTO-211H NIHBWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTITWM2OD14MEmuO|Qhdk1? MUDTRW5ITVJ?
GDM-1 MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH4dYtKSzVyPU[xOE4xQSCwTR?= MXjTRW5ITVJ?
TE-1 NGX2ZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\SU|JKSzVyPU[0Ok4yOiCwTR?= M2niXXNCVkeHUh?=
BT-474 M{HhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pTWM2OD14NEeuNFYhdk1? NFzHRWxUSU6JRWK=
KARPAS-45 NVTiO|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzZTWM2OD14NEeuOkBvVQ>? NEDrPGZUSU6JRWK=
MOLT-16 M1XSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZ2Nz65N{BvVQ>? MWPTRW5ITVJ?
KURAMOCHI MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fvV2lEPTB;NkW3MlUyKG6P MlzZV2FPT0WU
K-562 NEm2cIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ4OT61NUBvVQ>? MWXTRW5ITVJ?
EKVX NHS4VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\4ZXhKSzVyPU[3Nk44OSCwTR?= NXvwNGR3W0GQR1XS
GAK NH\EdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZ5NT6zJI5O NF[2dVZUSU6JRWK=
NCI-SNU-5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S4XWlEPTB;NkmwMlAyKG6P NUXkT281W0GQR1XS
NCI-H2126 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSwcJRWUUN3ME23NlYvQDdibl2= NXi1TIw1W0GQR1XS
CTV-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxTWM2OD15NESuPUBvVQ>? MlT4V2FPT0WU
SW962 NEnSfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTd2OD60OEBvVQ>? NFjLe3ZUSU6JRWK=
MONO-MAC-6 M3nM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTd3Nj65N{BvVQ>? MVLTRW5ITVJ?
NCI-H748 NWHQN5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDUeoZMUUN3ME23OVgvQTlibl2= NELjW2dUSU6JRWK=
NCI-H524 NYjWO3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD15OECuO|Mhdk1? NUfSSG5DW0GQR1XS
LS-123 NV7je2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHQTWM2OD15OUWuOlkhdk1? NU[zeHF4W0GQR1XS
NB7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;FcnZKSzVyPUixOE4yPCCwTR?= NHnO[|hUSU6JRWK=
LS-1034 NWHEbXVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTh{OD65PEBvVQ>? NELEWohUSU6JRWK=
TE-5 NH[4To5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xVYFKSzVyPUi4N{42PiCwTR?= NEfHNnhUSU6JRWK=
A704 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnZnV6UUN3ME24PVkvOTVibl2= M17YVXNCVkeHUh?=
TK10 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vQTGlEPTB;OUG2MlA{KG6P MXjTRW5ITVJ?
NCI-H345 NEjnWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVThOIx4UUN3ME25OFMvOjJibl2= M{TCbnNCVkeHUh?=
CGTH-W-1 NWDCb3l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLTTWM2OD17NEiuNVMhdk1? MYnTRW5ITVJ?
NCI-H510A NHfzXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTl6NT6xNkBvVQ>? NEHtTldUSU6JRWK=
NCI-H1963 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULOW3l3UUN3ME2xMlA{Ojl{IN88US=> MmX2V2FPT0WU
SCC-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHWW9bUUN3ME2xMlA{PDF2IN88US=> NVHyRZVrW0GQR1XS
EW-11 NXzhUm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\tdIxbUUN3ME2xMlA5PzR|IN88US=> M17kSnNCVkeHUh?=
CPC-N M1j1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjTcYZKSzVyPUGuNFg5KM7:TR?= NWTOXohwW0GQR1XS
NCI-H1417 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJPJBKSzVyPUGuNVIzPiEQvF2= NHHhT3NUSU6JRWK=
DG-75 NFfTOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzrTWM2OD1zLkG2Nlg2KM7:TR?= MnnGV2FPT0WU
HD-MY-Z MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjwfFBUUUN3ME2xMlE3PDF4IN88US=> NFHGSXdUSU6JRWK=
ATN-1 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrqWZN[UUN3ME2xMlI3OjB7IN88US=> MXPTRW5ITVJ?
KM-H2 NWf3[opjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO5O5dKSzVyPUGuNlY1ODhizszN MYDTRW5ITVJ?
NCI-H2081 NEHmWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECz[FFKSzVyPUGuNlY3OzdizszN NED6cJNUSU6JRWK=
HL-60 NHT4V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;tTWM2OD1zLkK2PVU6KM7:TR?= MoDFV2FPT0WU
DB M1zDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDyTWM2OD1zLkK3NlQzKM7:TR?= NXu5foFiW0GQR1XS
NCI-H1522 NXXreZJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwMki4PFch|ryP M3\TNnNCVkeHUh?=
AM-38 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4RWlKSzVyPUGuN|A4OiEQvF2= M3THfHNCVkeHUh?=
NCI-H446 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36wS2lEPTB;MT6zNlEzOSEQvF2= NWj6OIRnW0GQR1XS
SU-DHL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\yVZp5UUN3ME2xMlMzQDBzIN88US=> M{Gyb3NCVkeHUh?=
NH-12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\LZmlEPTB;MT6zOlM4PCEQvF2= NFji[ZZUSU6JRWK=
DMS-79 M{K1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofuTWM2OD1zLkO2PFY3KM7:TR?= MUDTRW5ITVJ?
NCI-H716 M3L5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HCOWlEPTB;MT6zPFk5PiEQvF2= NUnsO|lRW0GQR1XS
ML-2 NGrOWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jGUWlEPTB;MT60NVUzQSEQvF2= NVrMN2QxW0GQR1XS
NB10 M{\pOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwNE[2N|Ih|ryP MmToV2FPT0WU
ONS-76 NI[yfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXIcHJKSzVyPUGuOVM2PjlizszN MVrTRW5ITVJ?
LOUCY NXjMWJFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHxNnZKSzVyPUGuOVQ3PTdizszN MkPDV2FPT0WU
SCLC-21H NXywV25NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXPOVl6UUN3ME2xMlU5PTh{IN88US=> M2W1fHNCVkeHUh?=
TGW M1P6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOwWlJUUUN3ME2xMlY{QTd3IN88US=> MkSxV2FPT0WU
LXF-289 NUjHXIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fv[mlEPTB;MT63N|I3QCEQvF2= MmfXV2FPT0WU
BB49-HNC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXVOJhSUUN3ME2xMlc{PTh4IN88US=> NVvPNmJpW0GQR1XS
NCI-H747 NVHqNmc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1zLke1N|Q3KM7:TR?= NVzaZpdDW0GQR1XS
LU-165 NFvNfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwOES5PFYh|ryP M2\qXHNCVkeHUh?=
OMC-1 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwOUWwOlYh|ryP NWCyNJB1W0GQR1XS
RCC10RGB MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XCNGlEPTB;MT65OVgyPyEQvF2= NUK1XYdUW0GQR1XS
SW684 M2L5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTaTWM2OD1zLkm2NFk6KM7:TR?= M{LYdnNCVkeHUh?=
TE-8 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD2TWM2OD1{LkC1OVU6KM7:TR?= NXvn[3N5W0GQR1XS
SK-N-DZ Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOwXIZKSzVyPUKuNVMzPzRizszN MYjTRW5ITVJ?
EVSA-T MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwMUezNVUh|ryP NIXyN4FUSU6JRWK=
KASUMI-1 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMUi4NVUh|ryP MnfXV2FPT0WU
NKM-1 NHv4Sm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzSm1KSzVyPUKuNlU1PzJizszN NGfQRlJUSU6JRWK=
CAL-148 NGntcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPTWM2OD1{LkOzOlE1KM7:TR?= MYDTRW5ITVJ?
NCI-H64 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwM{SyN|Ih|ryP MmHyV2FPT0WU
KNS-81-FD MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\JZ5dKSzVyPUKuN|Y3OiEQvF2= NUTFU455W0GQR1XS
KM12 M{PMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4OJdIUUN3ME2yMlQxQDN7IN88US=> NYLxSlRzW0GQR1XS
SW954 NWriRm9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnYb|J2UUN3ME2yMlQ4Pzd7IN88US=> M1rPXnNCVkeHUh?=
NCI-H1395 NFXIdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwNUK2OFUh|ryP NYfwfZJvW0GQR1XS
DJM-1 NG\zR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfndnZKSzVyPUKuOlA3OyEQvF2= NV;Jc2pPW0GQR1XS
COLO-668 NYPQfYtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjRXZlKSzVyPUKuPFI3QTVizszN M1fmOXNCVkeHUh?=
NCI-H1436 NHrVbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwOEW2NVUh|ryP NGfxRnNUSU6JRWK=
LB2241-RCC NY\teHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuzZohKSzVyPUKuPFY5OzlizszN MojwV2FPT0WU
GT3TKB M2DVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H6eGlEPTB;Mj64PVA2PSEQvF2= M{SxV3NCVkeHUh?=
COLO-824 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwOEm3Olgh|ryP MnfxV2FPT0WU
ES1 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLOTWM2OD1{Lki5PFc6KM7:TR?= NV35b3JEW0GQR1XS
LB771-HNC NYfqdYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLXTWM2OD1{LkmwPVQ3KM7:TR?= Ml\RV2FPT0WU
GI-ME-N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwMEC5NFQh|ryP MVvTRW5ITVJ?
NALM-6 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfZTWM2OD1|LkCwPVM{KM7:TR?= NWXkeGllW0GQR1XS
LU-134-A M{DOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwMEW0NlUh|ryP M2fRdnNCVkeHUh?=
DMS-153 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0TWM2OD1|LkC1PFI1KM7:TR?= MknqV2FPT0WU
MZ1-PC Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC2eHdNUUN3ME2zMlA6ODd6IN88US=> NWfYfXFOW0GQR1XS
NCI-H1155 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X4ZWlEPTB;Mz6xNVYyKM7:TR?= MWrTRW5ITVJ?
CAS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzTTWM2OD1|LkGzO|A4KM7:TR?= MnW2V2FPT0WU
D-502MG NYWwUm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv6TWM2OD1|LkG0N|kh|ryP MWjTRW5ITVJ?
NCI-H2141 NHPjNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwMUe0OVIh|ryP MVXTRW5ITVJ?
NB6 NF6xdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3EeWk4UUN3ME2zMlE5OjV7IN88US=> NV2y[WpNW0GQR1XS
NCCIT NY\QZVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwMkG4NFkh|ryP NInLfVVUSU6JRWK=
NB69 NYPvb2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XtTGlEPTB;Mz6zNVg6OSEQvF2= MYXTRW5ITVJ?
JVM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1|LkO2OFM{KM7:TR?= MX\TRW5ITVJ?
K052 NUfYNI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCVGlEPTB;Mz6zO|k3QCEQvF2= M4HMVHNCVkeHUh?=
HCC2157 NYfqUIs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnLTWM2OD1|LkWzNlI5KM7:TR?= MmCyV2FPT0WU
KMOE-2 NF3WOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;QWWNrUUN3ME2zMlU1OjR{IN88US=> Mn3tV2FPT0WU
SF268 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwN{G1OVQh|ryP NXTzOXZQW0GQR1XS
CHP-126 NX;SXZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n0O2lEPTB;Mz63OlQ2QCEQvF2= Mny3V2FPT0WU
CP66-MEL MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4[Hc1UUN3ME2zMlc6ODl2IN88US=> M3;JSnNCVkeHUh?=
NCI-H69 M{fsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwMEG5N|Yh|ryP NXvqb3ZGW0GQR1XS
A253 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD12LkCyNVAyKM7:TR?= NWPBcldTW0GQR1XS
NB14 NGrPd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL0b4VKSzVyPUSuNVA1PzlizszN NUTCW4xUW0GQR1XS
NCI-H1694 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTDTWM2OD12LkGzNVEzKM7:TR?= MXjTRW5ITVJ?
NCI-H2196 M{[xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITqXJVKSzVyPUSuNVcyPjlizszN NHvDOXJUSU6JRWK=
TE-9 NGrBOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe4U4JLUUN3ME20MlE4PTh{IN88US=> MWnTRW5ITVJ?
D-283MED NVPJdmdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofITWM2OD12LkG4PFQh|ryP M3;Ue3NCVkeHUh?=
OCI-AML2 NI\ESXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwMUm0PFkh|ryP NE[5WohUSU6JRWK=
D-263MG Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwMkK5OlEh|ryP MknDV2FPT0WU
MPP-89 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq1Wm9JUUN3ME20MlI4OzB2IN88US=> M163VHNCVkeHUh?=
LAMA-84 NWXFO|Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XKPWlEPTB;ND6zNFQzOSEQvF2= MoTsV2FPT0WU
LB373-MEL-D NXXaV3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\pUJRUUUN3ME20MlM3Pzh7IN88US=> NYDIR|lyW0GQR1XS
UACC-257 NULXcotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRwM{m1N|Qh|ryP MVrTRW5ITVJ?
MC-CAR MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXqbphKSzVyPUSuOFM6QSEQvF2= NYK0XVhWW0GQR1XS
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq5TWM2OD12LkS0OFI4KM7:TR?= M4XEc3NCVkeHUh?=
P30-OHK MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XzOWlEPTB;ND62OlU5OSEQvF2= Ml3hV2FPT0WU
UACC-812 NETxOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yU2lEPTB;ND62PVE3OSEQvF2= MXvTRW5ITVJ?
CTB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwN{G1OVUh|ryP NUD4cINqW0GQR1XS
ALL-PO M3jmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\mTWM2OD12Lki0NFc4KM7:TR?= MXnTRW5ITVJ?
SK-MEL-2 M2q5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTRwOE[5OVUh|ryP NIKycldUSU6JRWK=
TC-YIK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSTWM2OD12Lkm3PVQzKM7:TR?= MmPxV2FPT0WU
NCI-H1882 NGLEXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jrfWlEPTB;NT6wNlAxOSEQvF2= NGXDUWRUSU6JRWK=
MHH-CALL-2 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G4ZWlEPTB;NT6wOVA1OiEQvF2= MmruV2FPT0WU
U-87-MG Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYflNmU4UUN3ME21MlA6PDZ4IN88US=> MmjFV2FPT0WU
NCI-H1092 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjCcmk2UUN3ME21MlI3PTV3IN88US=> MmrzV2FPT0WU
TE-441-T MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\kNXlSUUN3ME21MlI4QDJizszN MVXTRW5ITVJ?
SK-MEL-1 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD13LkK5NFQ1KM7:TR?= NHP1cIlUSU6JRWK=
EW-22 NFy5WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\0WXVZUUN3ME21MlI6PDZ4IN88US=> MXnTRW5ITVJ?
MZ7-mel NF\QNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6WWlEPTB;NT60NFY6OSEQvF2= NEfwXmlUSU6JRWK=
LP-1 M1X3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTVwNEGyPVEh|ryP M362R3NCVkeHUh?=
NCI-SNU-16 NHrOPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfpOllKSzVyPUWuOlQxPzRizszN MYrTRW5ITVJ?
LU-65 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n4XWlEPTB;NT63OlM4OyEQvF2= MWLTRW5ITVJ?
CW-2 NIn1OpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LVNGlEPTB;NT64OVk2QSEQvF2= NI\oeY9USU6JRWK=
WSU-NHL NVPCR4psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVwOUWxO|Qh|ryP M{\Ie3NCVkeHUh?=
IST-MES1 NVLLWWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrJ[pZKSzVyPUWuPVU1PDNizszN NEP6V5NUSU6JRWK=
U-266 NIixU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzWTWM2OD13Lkm4NlAzKM7:TR?= NVTUUJV7W0GQR1XS
TALL-1 NYHieXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rBWmlEPTB;Nj6xOFY5QCEQvF2= M3[1W3NCVkeHUh?=
Calu-6 NILoSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX6R5JKSzVyPU[uNVU{OTZizszN NVjXO41xW0GQR1XS
MMAC-SF NHOwUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ewbGlEPTB;Nj6xPFU2PiEQvF2= NVO0fWtFW0GQR1XS
NCI-H82 NIm3cmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ZTWM2OD14LkKwOFg6KM7:TR?= M4\QWXNCVkeHUh?=
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fSS2lEPTB;Nj6yOVg6PyEQvF2= Mn\xV2FPT0WU
SNU-C2B NEe0SJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rXXGlEPTB;Nj60NFk3QSEQvF2= Mn;FV2FPT0WU
BOKU MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\uTWM2OD14LkS3OVk4KM7:TR?= NHXHPHpUSU6JRWK=
C8166 M3HvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CycmlEPTB;Nj61OVkyOiEQvF2= Mle3V2FPT0WU
D-247MG M4TTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;OfXRKSzVyPUeuNFQ{PDdizszN NEO4SXlUSU6JRWK=
EW-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjlTWM2OD15LkC3NlkzKM7:TR?= M{POV3NCVkeHUh?=
KG-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW2ZVlSUUN3ME23MlYzPzN6IN88US=> MUHTRW5ITVJ?
REH M2fQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP2dJh1UUN3ME23MlY5OTB7IN88US=> NID4NGlUSU6JRWK=
U-698-M MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTdwOESzNVUh|ryP NHLseoRUSU6JRWK=
KP-N-RT-BM-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTdwOUOwNlkh|ryP NUjybXc2W0GQR1XS
MS-1 NXe1NXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXvTWM2OD15Lkm2NFQyKM7:TR?= MoO3V2FPT0WU
SNU-C1 M1fTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;NRWlEPTB;Nz65PFE6OiEQvF2= NVfzNYtQW0GQR1XS
SK-MM-2 M1nSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVNGlEPTB;OD6yOlA3PSEQvF2= NYLtZVV3W0GQR1XS
LAN-6 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJUIJwUUN3ME24MlMxODBzIN88US=> M4nyXXNCVkeHUh?=
NEC8 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLnTWM2OD16LkOwOlkyKM7:TR?= NIfJdGpUSU6JRWK=
NCI-H1770 NFeyRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC5TWM2OD16LkO4NFAzKM7:TR?= NEHmcGdUSU6JRWK=
D-336MG NVy4VldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H3e2lEPTB;OD60NFEyPiEQvF2= M1LjUHNCVkeHUh?=
COLO-829 NWDsTGN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLJ[Is3UUN3ME24MlQ5QDd7IN88US=> NIXPeWtUSU6JRWK=
LS-513 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn1VJJvUUN3ME24MlU6PTl7IN88US=> NGDvSWtUSU6JRWK=
YT NUTSOVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPsTWM2OD16Lk[yOFI4KM7:TR?= M1PWW3NCVkeHUh?=
EW-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvJZ41KSzVyPUiuO|Y2PCEQvF2= MXrTRW5ITVJ?
IST-SL1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHU[W9KSzVyPUiuPFY2PDNizszN MljoV2FPT0WU
CA46 M1znSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDaTWM2OD16Lkm1NFk5KM7:TR?= NYHqR4tyW0GQR1XS
NCI-H1838 M3q2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXO[Y9KSzVyPUiuPVg3ODJizszN Mn76V2FPT0WU
NCI-H719 NXPxd4t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjlRVhKSzVyPUmuNlUzPzlizszN NVjtSnF2W0GQR1XS
HCE-T MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;2XVlKSzVyPUmuN|A5PTFizszN NGjHVmFUSU6JRWK=
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX25SVF1UUN3ME25MlM3OTJ2IN88US=> NGPhUlNUSU6JRWK=
LB831-BLC NECwemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPHTWM2OD17Lke2OVIyKM7:TR?= NITyWVVUSU6JRWK=
SKM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIizNJVKSzVyPUmuPFU6PjNizszN NHTJZZVUSU6JRWK=
THP-1 NE\FOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwOU[5NVgh|ryP MkLGV2FPT0WU
SHP-77 M2PTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHRTWM2OD1zMD60NFch|ryP NI\NbVVUSU6JRWK=
EW-3 NGPxVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFyLk[yPFkh|ryP NFfsfXhUSU6JRWK=
KY821 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFyLke2N{DPxE1? MYnTRW5ITVJ?
NCI-SNU-1 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFzLkCyNVch|ryP NVfnRoJ6W0GQR1XS
HCC2218 NI\tOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy3UG1KSzVyPUGxMlM6QDZizszN NXu0VJp[W0GQR1XS
IM-9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1WWVKSzVyPUGxMlUyODZizszN MWnTRW5ITVJ?
NCI-H889 M1XQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnrTWM2OD1zMT61N|E{KM7:TR?= NE[3ZYxUSU6JRWK=
HDLM-2 M36ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfRNFJKSzVyPUGyMlQyPTlizszN M4fJZnNCVkeHUh?=
LB2518-MEL NVnLcFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1zMj62PFE2KM7:TR?= NXXjU2NQW0GQR1XS
NCI-H23 NHHo[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF|LkK0NlUh|ryP MkjyV2FPT0WU
NB17 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHCNoNKSzVyPUGzMlQ2PzlizszN MVTTRW5ITVJ?
NCI-H322M M2rIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK1fYQxUUN3ME2xOE41ODZ6IN88US=> NXnYTmJ[W0GQR1XS
SUP-T1 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnkeZhVUUN3ME2xOE41OTNizszN MlzMV2FPT0WU
ES3 NHHHcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz1TWM2OD1zNT6wO|A{KM7:TR?= Ml21V2FPT0WU
ES5 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqN5RKSzVyPUG1MlA4QDdizszN M1Tyc3NCVkeHUh?=
NCI-H1650 NV7OSpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4izOWlEPTB;MUWuOFk4QSEQvF2= NGnJ[XZUSU6JRWK=
NCI-H226 NVi1dXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD1zNT64O|Y5KM7:TR?= NEPQPJlUSU6JRWK=
COR-L88 NX\iWJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruOW82UUN3ME2xOk4{OTRizszN MWHTRW5ITVJ?
SCC-15 NEn1UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LTNGlEPTB;MU[uN|g3QSEQvF2= NYnqSZpkW0GQR1XS
GOTO NI\Ud5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPxTWM2OD1zNj60O|k{KM7:TR?= MY\TRW5ITVJ?
SIMA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXTTWM2OD1zNj60PFAzKM7:TR?= NF7UO3RUSU6JRWK=
NCI-H1299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r3SWlEPTB;MUeuNVU6OSEQvF2= MoXkV2FPT0WU
NCI-H1581 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyzTWM2OD1zNz60NlE6KM7:TR?= NXHSfoJqW0GQR1XS
MHH-NB-11 M2Dse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjSNZhFUUN3ME2xO{46Pjh|IN88US=> NUPWV3g1W0GQR1XS
MFM-223 NUCxPW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyTWM2OD1zOD6wOVM5KM7:TR?= Mn\oV2FPT0WU
ES7 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF6LkW0N|Eh|ryP MWTTRW5ITVJ?
JVM-3 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF6LkexO{DPxE1? NIHGWnlUSU6JRWK=
RL NWHVXYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorjTWM2OD1{MD6zPFgh|ryP NW\3XI54W0GQR1XS
EC-GI-10 NWfZNmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXF[3dVUUN3ME2yNU4zODRzIN88US=> M3rZW3NCVkeHUh?=
LNCaP-Clone-FGC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjLTWM2OD1{MT62O|Y5KM7:TR?= NYrqPFk4W0GQR1XS
IMR-5 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJzLki0PVQh|ryP MULTRW5ITVJ?
KP-N-YS M3THV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJzLki3OUDPxE1? MkDqV2FPT0WU
Mo-T M1;rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ{LkKxPFUh|ryP NIi4PHdUSU6JRWK=
NCI-H128 NEPGWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX3TWM2OD1{Mz61PFU{KM7:TR?= MVnTRW5ITVJ?
RH-1 M4KyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ|Lke4OlYh|ryP MnTSV2FPT0WU
NCI-H2171 NYPFOFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1O2lEPTB;MkSuNlQ5PSEQvF2= NH\hdWRUSU6JRWK=
RPMI-8866 M1i3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXaTWM2OD1{Nj63OFIh|ryP MoTyV2FPT0WU
SK-N-FI MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5eZhNUUN3ME2yO{4{QDFzIN88US=> MonnV2FPT0WU
LOXIMVI NVLxUlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[yTWM2OD1{Nz64NFUyKM7:TR?= Mn30V2FPT0WU
P31-FUJ M1XuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL6[FBKSzVyPUOxMlU{PzRizszN M4DqeXNCVkeHUh?=
KMS-12-PE Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DLdmlEPTB;NEmuOVMxOiEQvF2= NEi4dXhUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID